Abstract
As the action of aldose reductase (EC 1.1.1.21) is believed to be linked to the pathogenesis of diabetic complications affecting the nervous, renal, and visual systems, the development of therapeutic agents has attracted intense effort. We report the refined 1.8 A x-ray structure of the human holoenzyme complexed with zopolrestat, one of the most potent noncompetitive inhibitors. The zopolrestat fits snugly in the hydrophobic active site pocket and induces a hinge-flap motion of two peptide segments that closes the pocket. Excellent complementarity and affinity are achieved on inhibitor binding by the formation of 110 contacts (< or = 4 A) with 15 residues (10 hydrophobic), 13 with the NADPH coenzyme and 9 with four water molecules. The structure is key to understanding the mode of action of this class of inhibitors and for rational design of better therapeutics.
MeSH Terms
Aldehyde Reductase/antagonists & inhibitors,chemistry
Amino Acid Sequence
Benzothiazoles
Binding Sites
Humans
Models, Molecular
Molecular Structure
NADP/metabolism
Phthalazines/chemistry,metabolism
Protein Conformation
Protein Structure, Secondary
Recombinant Proteins/antagonists & inhibitors,chemistry
Thiazoles/chemistry,metabolism
X-Ray Diffraction/methods
Chemicals
Benzothiazoles
Phthalazines
Recombinant Proteins
Thiazoles
zopolrestat
NADP
Aldehyde Reductase
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Wilson D K
Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX 77030.
Tarle I
Petrash J M
Quiocho F A
References (11)
11 references, click to expand
-
Pharmacophor requirements of the aldose reductase inhibitor site.
Mol Pharmacol. 1983 Nov;24(3):521-31
PMID: 6415401
-
The role of aldose reductase in the development of diabetic complications.
Med Res Rev. 1988 Jul-Sep;8(3):325-52
PMID: 3136278
-
Aldose reductase from human psoas muscle. Purification, substrate specificity, immunological characterization, and effect of drugs and inhibitors.
J Biol Chem. 1989 Feb 15;264(5):2906-11
PMID: 2492526
-
Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
J Med Chem. 1991 Jan;34(1):108-22
PMID: 1899452
-
Novel NADPH-binding domain revealed by the crystal structure of aldose reductase.
Nature. 1992 Jan 30;355(6359):469-72
PMID: 1734286
-
Aldose reductase inhibitors: recent developments.
Prog Drug Res. 1993;40:99-161
PMID: 8356214
-
An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications.
Science. 1992 Jul 3;257(5066):81-4
PMID: 1621098
-
Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. Site-directed mutagenesis of Cys-80, -298, and -303.
J Biol Chem. 1992 Dec 5;267(34):24833-40
PMID: 1332968
-
The crystal structure of the aldose reductase.NADPH binary complex.
J Biol Chem. 1992 Dec 5;267(34):24841-7
PMID: 1447221
-
Molecular cloning of testicular 20 alpha-hydroxysteroid dehydrogenase: identity with aldose reductase.
Biochemistry. 1993 Feb 16;32(6):1401-6
PMID: 8431420
-
Studies on pig muscle aldose reductase. Kinetic mechanism and evidence for a slow conformational change upon coenzyme binding.
J Biol Chem. 1992 Apr 5;267(10):6510-7
PMID: 1551865